Skip to content
MarketScale
Demo
‹ Back to IndustriesSciences

BE STRATEGIC IN MANUFACTURING AUTOMATION: START WITH THE MANUFACTURING AUTOMATION AUDIT PROGRAM

Manufacturing is a competitive industry. Domestic manufacturers have been competing with overseas manufacturers for decades, which often offer lower cost labor. With competition high and approximately 96.4 percent of U.S. manufacturers qualifying as small businesses, per the U.S. Census Bureau, they are turning toward automation for leaner operations.[1] Automation Increases Productivity Automation delivers higher productivity…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Arc Specialties ArticlePromoted Content
Share
BE STRATEGIC IN MANUFACTURING AUTOMATION: START WITH THE MANUFACTURING AUTOMATION AUDIT PROGRAM

Key takeaways

01

Manufacturing is a competitive industry.

02

Domestic manufacturers have been competing with overseas manufacturers for decades, which often offer lower cost labor.

03

With competition high and approximately 96.4 percent of U.S.

Manufacturing is a competitive industry. Domestic manufacturers have been competing with overseas manufacturers for decades, which often offer lower cost labor. With competition high and approximately 96.4 percent of U.S. manufacturers qualifying as small businesses, per the U.S. Census Bureau, they are turning toward automation for leaner operations.[1]

Automation Increases Productivity

Automation delivers higher productivity and is represented in various applications including robotics. According to Robotic Industries Association (RIA), end-to-end automation in manufacturing can double or even triple throughput.[2] With automation, the equipment can also keep running, giving these manufacturers a competitive edge.

How Will Automation Help You?

Automation is no longer a nice thing to have. It’s imperative. According to a McKinsey study, 478 billion of the 749 billion working hours (64 percent) spent on manufacturing activities globally were automatable with current technology.[3] That’s over half, making it clear that automation is the answer for 21st century manufacturing.

But how will you know what automation application is right for your operations? It can be a challenging scope of work to take on, especially if you’re not experts in automation. ARC Specialties offers manufacturers a Manufacturing Automation Audit Program (MAAP), wherein we evaluate your processes and advise of areas that would be a good fit for automation. We empower manufacturers with automation. All it takes is a consultation and site visit, and you’ll have our recommendations.

Evaluating Automation

It’s not just about embracing automation in your business. It also matters how you integrate it into your workflows. To find these answers, there are nine key automation evaluation points:

  • Production volume
  • Part size
  • Part accuracy
  • Weld acceptance criteria
  • Weld process
  • Joint configuration
  • Material thickness
  • Base material
  • Technical capability of the facility

With these points evaluated, you can proceed with establishing automation to best fit your needs. While so many manufacturers are already using automation, some might not be doing so strategically. Sometimes, businesses rush to take advantage of technology without thinking it through. By partnering with us and allowing us to complete the MAAP, we’ll look at all nine of these points to determine the best set-up for your business.

How You’ll Benefit from MAAP

Go down a strategic path to automation, instead of rushing. In the long-term you’ll be glad you chose to start with a MAAP. From our analysis, key conclusions will be derived about how to employ automation. Those areas include:

  • Machined parts vs. forged parts: machined parts are consistent, whereas forged ones have differences
  • Automation best fits: high volume, low variety areas are best
  • With highly complex processes, more investment is needed in automation, which will impact the return on investment
  • Importance of implementing the technology; even in the best fit scenarios, automation must be engaged to work
  • Determining if the physical facility has the technical capabilities to support automation
  • Easy to use automation is necessary for operators to resolve any concerns with usage

At ARC Specialties, we’re serious about automation and making it work for your specific application. We aren’t keen to sell you something you don’t need. We are focused on being a partner to manufacturers as they embrace automation. Contact us today to talk more about MAAP and how we can help you automate.

Read more at arcspecialties.com

[1] https://www.census.gov/foreign-trade/Press-Release/edb/2015/edbrel.pdf

[2] https://www.robotics.org/blog-article.cfm/Benefits-of-Manufacturing-Automation/25

[3] https://www.mckinsey.com/business-functions/operations/our-insights/human-plus-machine-a-new-era-of-automation-in-manufacturing

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For Sciences teams

See how Sciences teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›
Keep exploring

More from Sciences

Sciences hubMore expert Sciences coverage.Explore →Executive Thought LeadershipPut researchers on the record.Explore →FinThriveComplex topics, made clear.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512